Decreased serum levels of SETD1A protein in patients with schizophrenia

SET domain-containing protein 1A (SETD1A) histone lysine N-methyltransferase may serve as a biomarker for the auxiliary diagnosis and treatment assessment of schizophrenia (SCZ). The aim of this study was to compare serum levels of SETD1A protein between patients with SCZ and health controls. Patien...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience letters 2024-06, Vol.833, p.137827, Article 137827
Main Authors: Wang, Zi-Han, Zhao, Yu-Qi, Yang, Shu-Ran, Guo, Xin-Ru, Gao, Zi-Bo, Bai, Wei, Kou, Changgui
Format: Article
Language:English
Subjects:
Adult
Biomarkers - blood
Case-Control Studies
ELISA
Female
Histone-Lysine N-Methyltransferase - blood
Humans
Male
Middle Aged
Schizophrenia
Schizophrenia - blood
Schizophrenia - diagnosis
Serum
SETD1A
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SET domain-containing protein 1A (SETD1A) histone lysine N-methyltransferase may serve as a biomarker for the auxiliary diagnosis and treatment assessment of schizophrenia (SCZ). The aim of this study was to compare serum levels of SETD1A protein between patients with SCZ and health controls. Patients with SCZ and health controls were recruited from the Sixth Hospital of Changchun and the ’Survey on Chronic Diseases and Risk Factors among Adults in Jilin Province’, respectively. The quantifications of lysine N-methyltransferase in peripheral serum were conducted by the ELISA method, and data was analyzed using the R software. Forty patients with SCZ (mean age: 33.97 ± 5.99 years) and forty healthy controls (mean age: 39.07 ± 4.62 years) were included. There was significantly lower concentration of SETD1A protein in the SCZ group compared with the control group (P 
ISSN:0304-3940
1872-7972
1872-7972
DOI:10.1016/j.neulet.2024.137827